(19)
(11) EP 1 809 599 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
04.04.2012 Bulletin 2012/14

(45) Mention of the grant of the patent:
10.12.2008 Bulletin 2008/50

(21) Application number: 05806455.1

(22) Date of filing: 17.10.2005
(51) International Patent Classification (IPC): 
C07C 401/00(2006.01)
(86) International application number:
PCT/BE2005/000146
(87) International publication number:
WO 2006/039763 (20.04.2006 Gazette 2006/16)

(54)

VITAMIN D3 ANALOGUES FOR THE PREVENTION AND TREATMENT OF BONE DISORDERS

VITAMIN-D3-ANALOGA ZUR PRÄVENTION UNDBEHANDLUNG VON KNOCHENERKRANKUNGEN

ANALOGUES DE LA VITAMINE D<SB>3</SB>POUR LA PREVENTION ET POUR LE TRAITEMENT DE TROUBLES OSSEUX

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
Designated Extension States:
AL BA HR MK YU

(30) Priority: 15.10.2004 GB 0422929

(43) Date of publication of application:
25.07.2007 Bulletin 2007/30

(73) Proprietors:
  • K.U.Leuven Research & Development
    3000 Leuven (BE)
  • Universiteit Gent
    9000 Gent (BE)

(72) Inventors:
  • BOUILLON, Roger
    B-3020 Winksele (BE)
  • VERSTUYF, Annemieke
    B-3050 Oud-Heverlee (BE)
  • DE CLERCQ, Pierre
    B-9000 Gent (BE)
  • VANDEWALLE, Maurits
    B-9000 Gent (BE)

(74) Representative: Bird, Ariane et al
Bird Goën & Co NV Klein Dalenstraat 42A
3020 Winksele
3020 Winksele (BE)


(56) References cited: : 
US-A- 6 017 907
   
  • Y WU ET AL.: "Vitamin D3: Synthesis of seco-C-9,11-bisnor-17-Methyl-1alpha,25-dih ydroxyvitamin D3 Analogues" BIORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 12, 2002, pages 1633-1636, XP002370278 cited in the application
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).